5,674 Shares in Haemonetics Corporation $HAE Bought by Versor Investments LP

Key Points

• Versor Investments LP has acquired 5,674 shares of Haemonetics Corporation, valued at approximately $361,000, indicating growing institutional interest in the company.
• Analyst ratings for Haemonetics show a consensus rating of "Moderate Buy" with a revised price target range between $70.00 and $86.00 from various firms.
• Haemonetics reported $1.10 EPS for the last quarter, surpassing analyst expectations, despite a 4.4% decline in year-over-year revenue.

Versor Investments LP purchased a new position in Haemonetics Corporation (NYSE:HAE - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,674 shares of the medical instruments supplier's stock, valued at approximately $361,000.

A number of other hedge funds also recently bought and sold shares of HAE. Envestnet Asset Management Inc. increased its position in Haemonetics by 9.6% during the fourth quarter. Envestnet Asset Management Inc. now owns 48,068 shares of the medical instruments supplier's stock valued at $3,753,000 after acquiring an additional 4,217 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Haemonetics by 1.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock valued at $77,470,000 after acquiring an additional 10,990 shares during the last quarter. MetLife Investment Management LLC increased its position in Haemonetics by 5.9% during the fourth quarter. MetLife Investment Management LLC now owns 57,766 shares of the medical instruments supplier's stock valued at $4,510,000 after acquiring an additional 3,241 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Haemonetics by 45.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,448 shares of the medical instruments supplier's stock valued at $347,000 after acquiring an additional 1,399 shares during the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in Haemonetics in the fourth quarter worth about $25,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Stock Down 0.0%

Shares of NYSE:HAE traded down $0.01 on Tuesday, reaching $55.23. The company had a trading volume of 729,197 shares, compared to its average volume of 1,298,360. Haemonetics Corporation has a 52-week low of $50.68 and a 52-week high of $94.99. The firm's 50 day simple moving average is $68.94 and its 200-day simple moving average is $66.20. The firm has a market capitalization of $2.66 billion, a PE ratio of 16.89, a PEG ratio of 1.02 and a beta of 0.40. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. During the same period last year, the business posted $1.02 EPS. The business's revenue was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on HAE. Raymond James Financial cut Haemonetics from a "strong-buy" rating to an "outperform" rating and reduced their price target for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Wall Street Zen cut Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Robert W. Baird began coverage on Haemonetics in a report on Thursday, June 26th. They set an "outperform" rating and a $87.00 price target for the company. Baird R W raised Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Finally, Barrington Research decreased their price target on Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Haemonetics presently has a consensus rating of "Moderate Buy" and a consensus target price of $85.18.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.